Lung Epithelial Cell Line Immune Responses to .

Theodore J Kottom, Eva M Carmona, Andrew H Limper
Author Information
  1. Theodore J Kottom: Thoracic Diseases Research Unit, Departments of Medicine and Biochemistry, Mayo Clinic, Rochester, MN 55905, USA. ORCID
  2. Eva M Carmona: Thoracic Diseases Research Unit, Departments of Medicine and Biochemistry, Mayo Clinic, Rochester, MN 55905, USA.
  3. Andrew H Limper: Thoracic Diseases Research Unit, Departments of Medicine and Biochemistry, Mayo Clinic, Rochester, MN 55905, USA.

Abstract

sp. are fungal pathogens and members of the Ascomycota phylum. Immunocompetent individuals can readily eliminate the fungus, whereas immunocompromised individuals can develop pneumonia (PJP). Currently, over 500,000 cases occur worldwide, and the organism is listed on the recently released WHO fungal priority pathogens list. Overall, the number of PJP cases over the last few decades in developed countries with the use of highly effective antiretroviral therapy has decreased, but the cases of non-HIV individuals using immunosuppressive therapies have significantly increased. Even with relatively effective current anti- therapies, the mortality rate remains 30-60% in non-HIV patients and 10-20% during initial episodes of PJP in HIV/AIDS patients. Although the role of alveolar macrophages is well studied and established, there is also well-established and emerging evidence regarding the role of epithelial cells in the immune response to fungi. This mini review provides a brief overview summarizing the innate immune response of the lung epithelium and various continuously cultured mammalian cell lines to .

Keywords

References

  1. Cold Spring Harb Perspect Med. 2014 Nov 03;4(12):a019828 [PMID: 25367973]
  2. Am J Physiol Lung Cell Mol Physiol. 2012 Mar 15;302(6):L504-11 [PMID: 22227205]
  3. FEMS Microbiol Lett. 2010 Oct;311(1):1-9 [PMID: 20528942]
  4. Acta Vet Scand. 1989;30(4):437-40 [PMID: 2640780]
  5. J Infect Dis. 2013 Jul;208(1):170-9 [PMID: 23532098]
  6. J Clin Invest. 1991 Aug;88(2):403-7 [PMID: 1830888]
  7. Eur Respir J. 2010 Oct;36(4):722-7 [PMID: 20223917]
  8. Biomed Res Int. 2022 Jun 21;2022:2064013 [PMID: 35774277]
  9. Am J Physiol. 1998 Jul;275(1):L118-25 [PMID: 9688943]
  10. Innate Immun. 2012 Oct;18(5):709-16 [PMID: 22334619]
  11. In Vitro Cell Dev Biol. 1992 Nov-Dec;28A(11-12):735-44 [PMID: 1282914]
  12. J Infect Dis. 1997 Mar;175(3):661-8 [PMID: 9041339]
  13. Lab Invest. 1986 Jun;54(6):609-15 [PMID: 3487003]
  14. mSphere. 2021 Aug 25;6(4):e0041121 [PMID: 34232078]
  15. Front Immunol. 2022 Nov 01;13:966814 [PMID: 36389688]
  16. J Lab Clin Med. 1991 Nov;118(5):492-9 [PMID: 1658169]
  17. Fungal Genet Biol. 2001 Dec;34(3):145-54 [PMID: 11728153]
  18. Eur J Immunol. 2021 Sep;51(9):2341-2344 [PMID: 34114658]
  19. Eur J Clin Invest. 1998 May;28(5):424-9 [PMID: 9650017]
  20. Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20545-20555 [PMID: 31548395]
  21. J Eukaryot Microbiol. 2003;50 Suppl:629 [PMID: 14736190]
  22. Eur J Clin Invest. 1999 Aug;29(8):717-22 [PMID: 10457157]
  23. J Biol Chem. 1994 Jan 21;269(3):2139-45 [PMID: 8294468]
  24. Nat Commun. 2016 Feb 22;7:10740 [PMID: 26899007]
  25. J Fungi (Basel). 2023 Feb 07;9(2): [PMID: 36836334]
  26. Infect Immun. 2003 Nov;71(11):6463-71 [PMID: 14573668]
  27. J Wildl Dis. 2022 Oct 1;58(4):897-901 [PMID: 36300952]
  28. J Infect Dis. 2022 Feb 1;225(3):525-530 [PMID: 34289046]
  29. Front Microbiol. 2021 May 20;12:681474 [PMID: 34093506]
  30. Front Cell Infect Microbiol. 2021 Dec 27;11:761596 [PMID: 35024355]
  31. Equine Vet J. 1993 Mar;25(2):103-8 [PMID: 8467767]
  32. Int J Biochem Cell Biol. 2010 Jan;42(1):1-4 [PMID: 19747565]
  33. Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1495-505 [PMID: 17307812]
  34. Am J Respir Cell Mol Biol. 2005 Jun;32(6):490-7 [PMID: 15746433]
  35. J Biol Chem. 2003 Jan 17;278(3):2043-50 [PMID: 12419803]
  36. Cell Microbiol. 2020 Jun;22(6):e13182 [PMID: 32017380]
  37. J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [PMID: 4357758]
  38. Front Fungal Biol. 2021 Sep 01;2:740845 [PMID: 37744131]
  39. Biophys J. 2010 Apr 21;98(8):1703-11 [PMID: 20409492]
  40. mBio. 2016 Dec 13;7(6): [PMID: 27965450]
  41. Infect Immun. 1994 Dec;62(12):5464-9 [PMID: 7960127]
  42. Microbes Infect. 2004 Aug;6(10):875-81 [PMID: 15310463]
  43. Vaccines (Basel). 2020 Jun 13;8(2): [PMID: 32545735]
  44. Sci Rep. 2017 Mar 06;7:43829 [PMID: 28262742]
  45. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11029-33 [PMID: 8248207]
  46. J Infect Dis. 1991 Mar;163(3):611-6 [PMID: 1899874]
  47. Dev Cell. 2018 Feb 5;44(3):297-312.e5 [PMID: 29408236]
  48. Mol Microbiol. 2008 Feb;67(4):747-61 [PMID: 18179594]
  49. J Immunol. 2013 Nov 1;191(9):4720-30 [PMID: 24078701]
  50. Am J Physiol. 1997 Dec;273(6):L1103-11 [PMID: 9435563]
  51. Front Immunol. 2022 Sep 15;13:988766 [PMID: 36225936]
  52. Respir Res. 2010 Jul 13;11:95 [PMID: 20626862]
  53. Front Immunol. 2021 Apr 29;12:670574 [PMID: 33995406]
  54. PLoS One. 2019 Jun 6;14(6):e0217684 [PMID: 31170201]
  55. Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Aug;262(2):230-9 [PMID: 3491475]
  56. Int J Mol Sci. 2021 Jun 18;22(12): [PMID: 34207342]
  57. Dan Med Bull. 2003 May;50(2):161-76 [PMID: 12812139]
  58. Am J Pathol. 1980 Jun;99(3):561-88 [PMID: 6966893]
  59. Microbiol Immunol. 2022 May;66(5):238-251 [PMID: 35229348]
  60. Front Immunol. 2023 Feb 09;14:1094464 [PMID: 36845149]
  61. Nat Microbiol. 2018 Jan;3(1):53-61 [PMID: 29133884]
  62. Nature. 1988 Aug 11;334(6182):519-22 [PMID: 2970013]
  63. Development. 2011 Aug;138(16):3533-43 [PMID: 21791528]
  64. Zentralbl Bakteriol Mikrobiol Hyg A. 1984 Mar;256(3):390-9 [PMID: 6610263]
  65. Infect Immun. 2005 May;73(5):2766-77 [PMID: 15845480]
  66. J Immunol. 2019 Oct 15;203(8):2239-2251 [PMID: 31501257]
  67. J Biol Chem. 2005 Feb 11;280(6):4864-72 [PMID: 15545264]

Grants

  1. R01 HL062150/NHLBI NIH HHS
  2. HL062150/NIH HHS

Word Cloud

Created with Highcharts 10.0.0individualsPJPcasesfungalpathogenscaneffectivenon-HIVtherapiespatientsroleimmuneresponsespmembersAscomycotaphylumImmunocompetentreadilyeliminatefunguswhereasimmunocompromiseddeveloppneumoniaCurrently500000occurworldwideorganismlistedrecentlyreleasedWHOprioritylistOverallnumberlastdecadesdevelopedcountriesusehighlyantiretroviraltherapydecreasedusingimmunosuppressivesignificantlyincreasedEvenrelativelycurrentanti-mortalityrateremains30-60%10-20%initialepisodesHIV/AIDSAlthoughalveolarmacrophageswellstudiedestablishedalsowell-establishedemergingevidenceregardingepithelialcellsfungiminireviewprovidesbriefoverviewsummarizinginnatelungepitheliumvariouscontinuouslyculturedmammaliancelllinesLungEpithelialCellLineImmuneResponsesCLRC-typelectinPneumocystisinflammationβ-glucans

Similar Articles

Cited By

No available data.